Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective
The development of targeted therapies has improved survival rates for patients with advanced non-small cell lung cancer (NSCLC). However, tissue biopsy is unfeasible or inadequate in many patients, limiting biomarker testing and access to targeted therapies. The increasing numbers of established and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Journal of Molecular Pathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5261/2/3/22 |
| _version_ | 1829092184912035840 |
|---|---|
| author | Umberto Malapelle Marcello Tiseo Ana Vivancos Joshua Kapp M. Josè Serrano Markus Tiemann |
| author_facet | Umberto Malapelle Marcello Tiseo Ana Vivancos Joshua Kapp M. Josè Serrano Markus Tiemann |
| author_sort | Umberto Malapelle |
| collection | DOAJ |
| description | The development of targeted therapies has improved survival rates for patients with advanced non-small cell lung cancer (NSCLC). However, tissue biopsy is unfeasible or inadequate in many patients, limiting biomarker testing and access to targeted therapies. The increasing numbers of established and emerging biomarkers with available targeted treatments highlights the challenges associated with sequential single-gene testing and limited tissue availability. Multiplex next-generation sequencing (NGS) offers an attractive alternative and represents a logical next step, and in cases where the tumour is inaccessible, tissue biopsy yields insufficient tumour content, or when the patient’s performance status does not allow a tissue biopsy, liquid biopsy can provide valuable material for molecular diagnosis. Here, we explore the role of liquid biopsy (i.e., circulating cell-free DNA analysis) in Europe. Liquid biopsies could be used as a complementary approach to increase rates of molecular diagnosis, with the ultimate aim of improving patient access to appropriate targeted therapies. Expert opinion is also provided on potential future applications of liquid biopsy in NSCLC, including for cancer prevention, detection of early stage and minimum residual disease, monitoring of response to therapy, selection of patients for immunotherapy, and monitoring of tumour evolution to enable optimal adaptation/combination of drug therapies. |
| first_indexed | 2024-03-10T07:32:45Z |
| format | Article |
| id | doaj.art-42ff0590d4bf497487c19e5b589dbfa0 |
| institution | Directory Open Access Journal |
| issn | 2673-5261 |
| language | English |
| last_indexed | 2024-03-10T07:32:45Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Molecular Pathology |
| spelling | doaj.art-42ff0590d4bf497487c19e5b589dbfa02023-11-22T13:45:16ZengMDPI AGJournal of Molecular Pathology2673-52612021-08-012325527310.3390/jmp2030022Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European PerspectiveUmberto Malapelle0Marcello Tiseo1Ana Vivancos2Joshua Kapp3M. Josè Serrano4Markus Tiemann5Department of Public Health, University of Naples Federico II, 80137 Naples, ItalyDepartment of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, 43126 Parma, ItalyCancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, SpainAmgen, Europe GmbH, 6343 Rotkreuz, SwitzerlandGENYO Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, SpainInstitute for Hematopathology Hamburg, 22547 Hamburg, GermanyThe development of targeted therapies has improved survival rates for patients with advanced non-small cell lung cancer (NSCLC). However, tissue biopsy is unfeasible or inadequate in many patients, limiting biomarker testing and access to targeted therapies. The increasing numbers of established and emerging biomarkers with available targeted treatments highlights the challenges associated with sequential single-gene testing and limited tissue availability. Multiplex next-generation sequencing (NGS) offers an attractive alternative and represents a logical next step, and in cases where the tumour is inaccessible, tissue biopsy yields insufficient tumour content, or when the patient’s performance status does not allow a tissue biopsy, liquid biopsy can provide valuable material for molecular diagnosis. Here, we explore the role of liquid biopsy (i.e., circulating cell-free DNA analysis) in Europe. Liquid biopsies could be used as a complementary approach to increase rates of molecular diagnosis, with the ultimate aim of improving patient access to appropriate targeted therapies. Expert opinion is also provided on potential future applications of liquid biopsy in NSCLC, including for cancer prevention, detection of early stage and minimum residual disease, monitoring of response to therapy, selection of patients for immunotherapy, and monitoring of tumour evolution to enable optimal adaptation/combination of drug therapies.https://www.mdpi.com/2673-5261/2/3/22cfDNActDNAliquid biopsynext-generation sequencingnon-small cell lung cancermolecular diagnostics |
| spellingShingle | Umberto Malapelle Marcello Tiseo Ana Vivancos Joshua Kapp M. Josè Serrano Markus Tiemann Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective Journal of Molecular Pathology cfDNA ctDNA liquid biopsy next-generation sequencing non-small cell lung cancer molecular diagnostics |
| title | Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective |
| title_full | Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective |
| title_fullStr | Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective |
| title_full_unstemmed | Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective |
| title_short | Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective |
| title_sort | liquid biopsy for biomarker testing in non small cell lung cancer a european perspective |
| topic | cfDNA ctDNA liquid biopsy next-generation sequencing non-small cell lung cancer molecular diagnostics |
| url | https://www.mdpi.com/2673-5261/2/3/22 |
| work_keys_str_mv | AT umbertomalapelle liquidbiopsyforbiomarkertestinginnonsmallcelllungcanceraeuropeanperspective AT marcellotiseo liquidbiopsyforbiomarkertestinginnonsmallcelllungcanceraeuropeanperspective AT anavivancos liquidbiopsyforbiomarkertestinginnonsmallcelllungcanceraeuropeanperspective AT joshuakapp liquidbiopsyforbiomarkertestinginnonsmallcelllungcanceraeuropeanperspective AT mjoseserrano liquidbiopsyforbiomarkertestinginnonsmallcelllungcanceraeuropeanperspective AT markustiemann liquidbiopsyforbiomarkertestinginnonsmallcelllungcanceraeuropeanperspective |